


Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Application Number	09/989,620
	Filing Date	November 20, 2001
	First Named Inventor	Nobufusa SERIZAWA
	Group Art Unit	1614
	Examiner Name	
Sheet 1 of 6	Attorney Docket Number	01625CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits [*]	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
32		4,912,112		SEYDEL et al.	3-27-1990	
		COPY OF PAPERS ORIGINALLY FILED		COPY OF PAPERS ORIGINALLY FILED		

FOREIGN PATENT DOCUMENTS

Exam. Inits [*]	Cite No ¹	off ¹	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
32		JP	2-237935 0	A	KOBAYASHI et al.	9-20-1990		*
32		WIPO	WO 91/10448 0	A1	KRAMMER	7-25-1991		
32		EP	0 909 816 0	A1	SERIZAWA et al.	4-21-1999		
32		EP	0 866 131 0	A2	SERIZAWA et al.	9-23-1998		
32		EP	0 709 097 0	A1	NISHIOKA et al.	5-1-1996		
32		WIPO	WO 92/084610	A1	BLANEY et al.	5-29-1992		
32		WIPO	WO 86/05181 0	A1	TAYLOR et al.	9-12-1986		
32		EP	0 021 292 0	A1	GRIVSKY et al.	1-7-1981		
Examiner Signature					Date Considered	3-18-03		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. See kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Place a check here if English translation is attached.

DATE MAILED: JANUARY 29, 2002

*ENGLISH LANGUAGE ABSTRACT ENCLOSED

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	09/989,620
Filing Date	November 20, 2001
First Named Inventor	Nobufusa SERIZAWA et al.
Group Art Unit	1614
Examiner Name	

Sheet	2	of	6	Attorney Docket Number	01625CIP/HG
-------	---	----	---	------------------------	-------------

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

**COPY OF PAPERS
ORIGINALLY FILED**

FOREIGN PATENT DOCUMENTS

Exam Inits*	Cite No ¹	offc ¹	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
32		EP	0 897 724 0	A1	MIYASAKA et al.	2-24-1999		
32		EP	0 334 636 0	A2	AKIMOTO et al.	9-27-1989		
32		WIPO	WO 93/13079 0	A1	JONES et al.	7-8-1993		
32		WIPO	WO 95/09845 0	A1	GOSSETT et al.	4-13-1995		
32		WIPO	WO 91/10666	A1	ABRAHAM	7-25-1991		
32		JP	5-503281 0	A	KRAMMER	6-3-1993		** 9/9/03

Examiner
Signature

Date
Considered

3-18-03


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. See kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Place a check here if English translation is attached.

DATE MAILED: JANUARY 29, 2002

**FAMILY MEMBER OF WO 91/10448



Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	09/989,620
		Filing Date	November 20, 2001
		First Named Inventor	Nobufusa SERIZAWA
		Group Art Unit	1614
		Examiner Name	
Sheet 1 of 6	Attorney Docket Number		01625CIP/HG
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
32	1	KERR et al., "APOPTOSIS: A BASIC BIOLOGICAL PHENOMENON WITH WIDE-RANGING IMPLICATIONS IN TISSUE KINETICS", <u>Br. J. Cancer</u> , <u>26</u> , (1972), pp. 239-257.	
32	2	NAKAYAMA et al., "The Selection of T Cell and Apoptoss", <u>Mebio</u> , <u>12</u> , (10), (1995), pp. 79-86.	*
32	3	YONEHARA et al., "A CELL-KILLING MONOCLONAL ANTIBODY (ANTI-Fas) TO A CELL SURFACE ANTIGEN CO-DOWNREGULATED WITH THE RECEPTOR OF TUMOR NECROSIS FACTOR", <u>J. Exp. Med.</u> , <u>169</u> , (1989), pp. 1747-1756.	
32	4	LOETSCHER et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor", <u>Cell</u> , <u>61</u> , (1990), pp. 351-359.	
32	5	TSUBATA et al., "B-Cell Apoptosis Induced by Antigen Receptor Crosslinking is Blocked by a T-Cell signal through CD40", <u>NATURE</u> , <u>364</u> , (1993), pp. 645-648.	
32	6	JENNE et al., "Granzymes, a Family of Serine Proteases Released from Granules of Cytolytic T Lymphocytes upon T Cell Receptor Stimulation", <u>Immunological Reviews</u> , <u>103</u> , (1988), pp. 53-71.	
32	7	MCCARTY, "ARTHRITIS AND ALLIED CONDITIONS", <u>A Textbook of Rheumatology</u> , 10 th Edition (1985), Lea & Febiger, pp. xvii-xxii.	
32	8	NAKAJIMA et al., "APOPTOSIS AND FUNCTIONAL FAS ANTIGEN IN RHEUMATOID ARTHRITIS SYNOVIOCYTES", <u>ARTHRITIS & RHEUMATISM</u> , <u>38</u> , (4), (1995), pp. 485-491.	
32	9	AONO et al., "Inducing Apoptosis by Using Anti Fas Antibody Against Chronic Rheumatism Synovial Cells", <u>38th Japan Rheumatic Society Summary Collection</u> , (1994), p. 487.	*
Examiner Signature		Date Considered	3-18-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


* Unique citation designation number. Place a check here if English translation is attached.

DATE MAILED: JANUARY 29, 2002


COPY OF PAPERS
ORIGINALLY FILED

*ENGLISH LANGUAGE ABSTRACT ENCLOSED

RECEIVED
 FEB 04 2002
 TECH CENTER 1600/29001

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	09/989,620
		Filing Date	November 20, 2001
		First Named Inventor	Nobufusa SERIZAWA
		Group Art Unit	1614
		Examiner Name	
Sheet 4 of 6	Attorney Docket Number		01625CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
32		DAO et al., "Relation of bcl-2 and c-myc expression to apoptosis in a human leukemia T cell line induced by natural human tumor necrosis factor- α ", <u>PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, Japanese Journal of Cancer Research</u> , 53 Annual Meeting, Nagoya 1994, Hesei 6, p. 338.	
32	0	TRAUTH et al., "Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis", <u>SCIENCE</u> , 245, (1989), PP. 301-305.	
32	0	KALDEN, "Anti-TNF- α and Other Treatment Principles for RA", 7 th International Rheumatology Symposium in Kyoto, (1998), pp. 12-13.	
32	0	MCGAHON et al., "Chemotherapeutic Drug-Induced Apoptosis in Human Leukaemic Cells is Independent of the FAS (APO-1/CD95) Receptor/Ligand System", <u>British Journal of Haematology</u> , 101, (1998), pp. 539-547.	
32	0	MIZUTANI et al., "Doxorubicin Sensitizes Human Bladder Carcinoma Cells to Fas-Mediated Cytotoxicity", <u>American Cancer Society</u> , 79, (6), (1997), pp. 1180-1189.	
32	0	SERIZAWA, "Trials on the Development of Drug by an Novel Anti-Fas Monoclonal Antibody", <u>Saishin-igaku</u> , 54, (4), (1999), pp. 917-924.	0
32	0	"Edatrexate", <u>The Merck Index</u> , 3553, 12 th Edition, (1996), pp. 592-593.	
32	0	MIZUTANI et al., "SENSITIZATION OF HUMAN BLADDER CANCER CELLS TO FAS-MEDIATED CYTOTOXICITY BY CIS-DIAMMINEDICHLOROPLATINUM", <u>J. of Urology</u> , 160, (2), (1998), pp. 561-571.	
32	0	"Trimetrexate", <u>The Merck Index</u> , 9851, 12 th Edition, (1996), p. 1656.	
Examiner Signature			Date Considered 3-18-03


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. Place a check here if English translation is attached.


DATE MAILED: JANUARY 29, 2002

*ENGLISH LANGUAGE ABSTRACT ENCLOSED

COPY OF PAPERS
ORIGINALLY FILED

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	09/989,620	RECEIVED FEB 04 2002 TECH CENTER 1600/2900
		Filing Date	November 20, 2001	
		First Named Inventor	Nobufusa SERIZAWA	
		Group Art Unit	1614	
		Examiner Name		
Sheet	of	6	Attorney Docket Number	01625CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
34	0	"Brodinoprim", <u>The Merck Index</u> , 12 th Edition, <u>1401</u> , (1996), p. 226.		
32	0	KOTAKE et al., "Synthesis and Antitumor Activities of Novel 6-5 Fused Ring Heterocycle Antifolates: N-[4(ω(2-Amino-4-Substituted-6,7-Dihydrocyclopenta[d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic Acids", <u>J. Med. Chem.</u> , <u>37</u> , (11), (1994), pp. 1616-1624.		
42	0	FAESSEL et al., "Super in Vitro Synergy between Inhibitors of Dihydrofolate Reductase and Inhibitors of Other Folate-requiring Enzymes: The Critical Role of Polyglutamylolation", <u>CANCER RESEARCH</u> , <u>58</u> , (14), (1998), pp. 3036-3050.		
32	0	ROSOWSKY et al., "Synthesis and Biological Activity of Methotrexate Analogues with Two Acid Groups and a Hydrophobic Aromatic Ring in the Side Chain", <u>J. Med. Chem.</u> , <u>34</u> , (2), (1991), pp. 574-579.		
32	0	HUGHES et al., "Anti-Pneumocystis carinii Activity of PS-15, a New Biguanide Folate Antagonist", <u>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY</u> , <u>37</u> , (7), (1993), pp. 1417-1419.		
32	0	GENESTIER et al., "Immunosuppressive Properties of Methotrexate: Apoptosis and Clonal Deletion of Activated Peripheral T Cells", <u>J. Clin. Invest.</u> , <u>102</u> , (2), (1998), pp. 322-328.		
32	0	NISHIMURA-MORITA et al., "Amelioration of Systemic Autoimmune Disease by the Stimulation of Apoptosis-Promoting Receptor Fas with Anti-Fas mAb", <u>International Immunology</u> , <u>9</u> (12), (1997), pp. 1793-1799.		
32	0	FUJISAWA, "Anti-Fas mAb Therapy in Murine Arthritis", <u>Molecular Medicine</u> , <u>33</u> , (11), (1996), pp. 1254-1261.	0	
32	0	FUJISAWA et al., "Therapeutic Effect of Anti-Fas Antibody on Arthritis in HTLV-I Tax Transgenic Mice", <u>J. Clin. Invest.</u> , <u>98</u> , (2), (1998), pp. 271-278.		
Examiner Signature			Date Considered	3-18-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. Place a check here if English translation is attached.

DATE MAILED: JANUARY 29, 2002

*ENGLISH LANGUAGE ABSTRACT ENCLOSED

**COPY OF PAPERS
ORIGINALLY FILED**



Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number ⁴	09/989,620	
		Filing Date	November 20, 2001	
		First Named Inventor	Nobufusa SERIZAWA	
		Group Art Unit	1614	
		Examiner Name		
Sheet 	of	6	Attorney Docket Number	01625CIP/HG

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
32	1	SAKAI et al., "POTENTIAL WITHDRAWAL OF RHEUMATOID SYNOVIUM BY THE INDUCTION OF APOPTOSIS USING A NOVEL IN VIVO MODEL OF RHEUMATOID ARTHRITIS", <u>ARTHRITIS & RHEUMATISM</u> , <u>41</u> , (7), (1998), pp. 1251-1257.	
32	1	HASUNUMA et al., "Induction of Fas-Dependent Apoptosis in Synovial Infiltrating Cells in Rheumatoid Arthritis", <u>Int. Immunol.</u> , <u>8</u> , (10), (1996), pp. 1595-1602.	
32	1	SUMIDA et al., "Rheumatoid Arthritis and Apoptosis", <u>Intern. Med.</u> , <u>37</u> , (2), (1998), pp. 184-188.	
		COPY OF PAPERS ORIGINALLY FILED	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Place a check here if English translation is attached.

DATE MAILED: JANUARY 29, 2002